Alnylam Pharmaceuticals Inc (ALNY)
NASDAQ · Healthcare · Biotechnology
Alnylam Pharmaceuticals Inc is a Healthcare company with a market capitalization of $38.90B and a trailing P/E ratio of 73.0.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | April 30, 2026 | $1.99 | $1.47 | +35.4% |
| Q4 2025 | February 12, 2026 | $1.25 | $1.50 | -16.7% |
| Q3 2025 | October 30, 2025 | $2.90 | $1.75 | +65.7% |
| Q2 2025 | July 31, 2025 | $0.32 | $0.15 | +113.3% |
| Q1 2025 | May 1, 2025 | $-0.01 | $-0.37 | +97.3% |
| Q4 2024 | February 13, 2025 | $0.06 | $-0.14 | +142.9% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc's market cap?
As of June 29, 2026, Alnylam Pharmaceuticals Inc (ALNY) has a market capitalization of $38.90B.
What is Alnylam Pharmaceuticals Inc's P/E ratio?
Alnylam Pharmaceuticals Inc trades at a trailing price-to-earnings (P/E) ratio of 73.0. Its forward P/E is 31.3.
Does Alnylam Pharmaceuticals Inc pay a dividend?
Alnylam Pharmaceuticals Inc does not currently pay a dividend.
What sector is ALNY in?
Alnylam Pharmaceuticals Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Alnylam Pharmaceuticals Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Alnylam Pharmaceuticals Inc reported revenue of $3.71B and net income of $313.75M.
Ask your own questions about ALNY
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.